Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
source: shutterstock.com

Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD

Pfizer has recently paused its Phase III clinical trial that has been assessing the Duchenne muscular dystrophy candidate fordadistrogene movaparvovec. The Phase II DAYLIGHT trial (NCT05429372), enrolled ten boys ages…

Continue Reading Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE
source: shutterstock.com

FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE

According to a story from Globe Newswire, the biopharmaceutical company Catalyst Pharmaceuticals has recently announced an update to the company's supplemental New Drug Application (sNDA) for its drug amifampridine (marketed…

Continue Reading FDA Approves Dosage Boost for Lambert-Eaton Myasthenic Syndrome Drug FIRDAPSE
FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
source: pixabay.com

FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia

Three years after the U.S. Food and Drug Administration (FDA) first placed a full clinical hold on Larimar Therapeutics’ Phase 2 clinical study, the hold has officially been lifted. The…

Continue Reading FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia